November 05, 2018
The 90th edition of the HPRA drug safety newsletter.
The 90th edition of the HPRA drug safety newsletter includes information on the following medicines:
- Rivaroxaban (Xarelto) – Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement in a prematurely stopped clinical trial.
- Insulin-containing products -0 Risks of medication errors associated with extraction of insulin from pre-filled pens and cartridges for reusable pens.
- Hydrochlorothiazide (HCTZ) – Risk of non-melanoma skin cancer (NMSC)
- Dolutegravir – Neural tube defects reported in infants.